The evaluation of split renal function (SRF) is a critical issue in living kidney donations and can be evaluated using nuclear renography (NR) or computerized tomography (CT), with unclear comparative advantages. We conducted this retrospective study in 193 donors to examine the correlation of SRF assessed by NR and CT volumetry and compared their ability to predict remaining donor renal function at 1 year, through multiple approaches. A weak correlation between imaging techniques for evaluating the percentage of the remaining kidney volume was found in the global cohort, with an R2 = 0.15. However, the Bland–Altman plot showed an acceptable agreement (95% of the difference between techniques falling within − 8.51 to 6.11%). The predicted and observed eGFR one year after donation were calculated using the CKD-EPI, and CG/BSA equations. CT volume showed a better correlation than NR for both formulas (adjusted R2 of 0.42. and 0.61 vs 0.37 and 0.61 for CKD-EPI and CG/ BSA equations, respectively). In non-nested modeling tests, CT volumetry was significantly superior to NR for both equations. CT volumetry performed better than NR in predicting the estimated renal function of living donors at 1-year, independently from the eGFR equation.
A predictive model to estimate post-donation glomerular filtration rate (eGFR) and risk of CKD at 1-year was developed from a Toulouse-Rangueil cohort in 2017 and showed an excellent correlation to the observed 1-year post-donation eGFR. We retrospectively analyzed all living donor kidney transplants performed at a single center from 1998 to 2020. Observed eGFR using CKD-EPI formula at 1-year post-donation was compared to the predicted eGFR using the formula eGFR (CKD-EPI, mL/min/1.73 m2) = 31.71+ (0.521 × preoperative eGFR) − (0.314 × age). 333 donors were evaluated. A good correlation (Pearson r = 0.67; p < 0.001) and concordance (Bland-Altman plot with 95% limits of agreement −21.41–26.47 mL/min/1.73 m2; p < 0.001) between predicted and observed 1-year post-donation eGFR were observed. The area under the ROC curve showed a good discriminative ability of the formula in predicting observed CKD at 1-year post-donation (AUC = 0.83; 95% CI: 0.78–0.88; p < 0.001) with optimal cutoff corresponding to a predicted eGFR of 65.25 mL/min/1.73 m2 in which the sensibility and specificity to predict CKD were respectively 77% and 75%. The model was successfully validated in our cohort, a different European population. It represents a simple and accurate tool to assist in evaluating potential donors.
A living donor (LD) kidney transplant is the best treatment for kidney failure, but LDs safety is paramount. We sought to evaluate our LDs cohort’s longitudinal changes in estimated glomerular filtration rate (eGFR). We retrospectively studied 320 LDs submitted to nephrectomy between 1998 and 2020. The primary outcome was the eGFR change until 15 years (y) post-donation. Subgroup analysis considered distinct donor characteristics and kidney function reduction rate (%KFRR) post-donation [−(eGFR6 months(M)–eGFRpre-donation)/eGFRpre-donation*100]. Donors had a mean age of 47.3 ± 10.5 years, 71% female. Overall, LDs presented an average eGFR change 6 M onward of +0.35 mL/min/1.73 m2/year. The period with the highest increase was 6 M–2 Y, with a mean eGFR change of +0.85L/min/1.73 m2/year. Recovery plateaued at 10 years. Normal weight donors presented significantly better recovery of eGFR +0.59 mL/min/1.73 m2/year, compared to obese donors −0.18L/min/1.73 m2/year (p = 0.020). Noteworthy, these results only hold for the first 5 years. The subgroup with a lower KFRR (<26.2%) had a significantly higher decrease in eGFR overall of −0.21 mL/min/1.73 m2/year compared to the groups with higher KFRR (p < 0.001). These differences only hold for 6 M–2 Y. Moreover, an eGFR<50 mL/min/1.73 m2 was a rare event, with ≤5% prevalence in the 2–15 Y span, correlating with eGFR pre-donation. Our data show that eGFR recovery is significant and may last until 10 years post-donation. However, some subgroups presented more ominous kidney function trajectories.
Living donor (LD) kidney transplantation is the optimal treatment for elective end-stage kidney disease (ESKD) patients. However, concerns about the long-term health risks for donors, including hypertension, remain incompletely defined. We aimed to determine the incidence and predictors of hypertension after kidney donation and to assess its association with estimated glomerular filtration rate (eGFR) trajectories over time. We conducted a retrospective cohort study of 300 LD who underwent nephrectomy between 1998 and 2020, after excluding those with pre-donation hypertension. Donors were followed for a mean of 6.4 ± 4.5 years The primary outcome was the development of de novo hypertension, defined by office blood pressure measurements exceeding 140/90 mmHg or initiation of antihypertensive therapy. Predictors of post-donation hypertension were evaluated using Cox regression analysis, and the association with longitudinal changes in eGFR was assessed using linear mixed-effects models. Hypertension developed in 30% of the cohort, with an incidence of 21% at 5 years and over 50% at 15 years post-donation. Higher body mass index (BMI) (HR 1.074 per Kg/m2, P = 0.039), dyslipidemia (HR 1.959, P = 0.035), and elevated systolic (HR 1.030 per mmHg, P = 0.009) and diastolic blood pressure (HR 1.036 per mmHg, P = 0.039) were independently associated with an increased risk of hypertension post-donation. The development of hypertension was associated with a modest but statistically significant decline in eGFR over time (-0.03 vs. +0.40 ml/min/year, P = 0.026). No donor progressed to ESKD during follow-up and cardiovascular events were rare in the cohort. In conclusion, hypertension was a frequent complication post-donation in this Southern European cohort and was associated with modifiable risk factors, as higher BMI and dyslipidemia. While the associated decline in renal function over time is modest, these findings highlight the importance of long-term monitoring and proactive management of cardiovascular risk factors in living kidney donors. These results should inform pre-donation counseling, post-donation follow-up strategies, and further research into interventions that may mitigate hypertension risk while preserving donor health.